Interpretative immune targets and contemporary position for vaccine development against SARS‐CoV‐2: A systematic review

Abstract

The year 2020 started with the emergence of novel coronavirus, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), which causes COVID‐19 infection. Soon after the first evidence was reported in Wuhan, China, the World Health Organization declared global public health emergency and imminent need to understand the pathogenicity of the virus was required in limited time. Once the genome sequence of the virus was delineated, scientists across the world started working on the development of vaccines. Although, some laboratories have been using previously developed vaccine platforms from severe acute respiratory syndrome coronavirus (SARS) and middle east respiratory syndrome‐related coronavirus and apply them in COVID‐19 vaccines due to genetic similarities between coronaviruses. We have conducted a literature review to assess the background and current status of COVID‐19 vaccines. The worldwide implementation and strategies for COVID‐19 vaccine development are summarized from studies reported in years 2015–2020. While discussing the vaccine candidates, we have also explained interpretative immune responses of SARS‐CoV‐2 infection. There are several vaccine candidates at preclinical and clinical stages; however, only 42 vaccines are under clinical trials. Therefore, more industry collaborations and financial supports to COVID‐19 studies are needed for mass‐scale vaccine development. To develop effective vaccine platforms against SARS‐CoV‐2, the genetic resemblance with other coronaviruses are being evaluated which may further promote fast‐track trials on previously developed SARS‐CoV vaccines.

Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

“…For millions of people who have received the new vaccines, few side effects, if any, and vaccine development continue at an increasing pace [ 7 ]. Real-world safety monitoring and reporting is established in most countries.…”

Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines

“…It is not the only such approach in the context of the development of a vaccine preparation against SARS-CoV-2. The list of preclinical and clinical trials also includes an attenuated influenza vector vaccine (BiOCAD Global), a recombinant influenza A vaccine (Rospotrebnadzor) and an attenuated influenza virus vector expressing the S protein from SARS-CoV-2 (Fundação Oswaldo Cruz and Instituto Buntantan) [107].…”

Clinical data to be used as a foundation to combat Covid-19 vaccine hesitancy

“…A number of COVID-19 vaccines have been approved and are in human clinical trials in the United States as of October 27, 2020. 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 Covid-19 vaccine side effects and warnings are described as short-term side effects that were observed in leading vaccine trials 52 , 53 and post marketed vaccine administration and include: Injection site pain and redness 84%, Fatigue 63%, Myalgia, or muscle pain 14.8%, Arthralgia or joint pain 24%, Headache 55%, and Fever 14%. On December 8, 2020, the United Kingdom reported that two patients who were injected with Pfizer's recently approved coronavirus vaccine had to be treated for serious adverse reactions, which has led to warnings that those with “significant” allergies may not be able to get the vaccine.…”